Dendreon Corp fka DNDNQ

[rancherho]

Help, calling iwfal. Yesterday, CEGE's CEO stated at the JPM conference that interim results were now expected in its 600 patient Vital 1 trial in early 1H08. Vital-1 was fully enrolled with an actual 625 patients with asymptomatic AIPC in early July 2007 and compares high dose GVAX with boosters with boosters ceasing upon any subsequent therapy (eg, Taxotere) vs. Taxotere alone. Taxotere is reported to have median survival of 22 to 23 months in asymptomatic AIPC. The 32 patients in the GVAX high dose subgroup in its Phase 2 trials in AIPC had a median survival of 35 months. A developing issue is whether this near term maturing of interim data gives any clue as to whether statistically significant results are even possible. Two Yahoo MB posts opine on this (one is mine):
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=tm&bn=3352&tid=42344&mid=42387&tof=5&rt=1&frt=2&off=1

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_C/threadview?m=tm&bn=3352&tid=42388&mid=42388&tof=1&frt=2

While this is a DNDN MB, the timing and results of the interim and final analysis of CEGE's Vital 1 and Vital 2 trials in AIPC should be of obvious interest to any DNDN investor.
I realize that your skepticism of any statements from biotech companies is well deserved,but your thoughts would be much appreciated.